T-cell immune profile in blood of systemic mastocytosis: Association with disease features.
cytotoxic T cells
helper T cells
lymphocytes
mast cells
systemic mastocytosis
Journal
Allergy
ISSN: 1398-9995
Titre abrégé: Allergy
Pays: Denmark
ID NLM: 7804028
Informations de publication
Date de publication:
01 Feb 2024
01 Feb 2024
Historique:
revised:
02
01
2024
received:
28
07
2023
accepted:
16
01
2024
medline:
1
2
2024
pubmed:
1
2
2024
entrez:
1
2
2024
Statut:
aheadofprint
Résumé
Systemic mastocytosis (SM) is a heterogeneous disease characterized by an expansion of KIT-mutated mast cells (MC). KIT-mutated MC display activated features and release MC mediators that might act on the tumour microenvironment and other immune cells. Here, we investigated the distribution of lymphocyte subsets in blood of patients with distinct subtypes of SM and determined its association with other disease features. We studied the distribution of TCD4 SM patients showed decreased counts (vs. HD) of TCD4 Our results reveal altered T- and NK-cell immune profiles in blood of SM, which vary per disease subtype, the pattern of involvement of haematopoiesis by KIT
Sections du résumé
BACKGROUND
BACKGROUND
Systemic mastocytosis (SM) is a heterogeneous disease characterized by an expansion of KIT-mutated mast cells (MC). KIT-mutated MC display activated features and release MC mediators that might act on the tumour microenvironment and other immune cells. Here, we investigated the distribution of lymphocyte subsets in blood of patients with distinct subtypes of SM and determined its association with other disease features.
METHODS
METHODS
We studied the distribution of TCD4
RESULTS
RESULTS
SM patients showed decreased counts (vs. HD) of TCD4
CONCLUSION
CONCLUSIONS
Our results reveal altered T- and NK-cell immune profiles in blood of SM, which vary per disease subtype, the pattern of involvement of haematopoiesis by KIT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : HORIZON EUROPE Marie Sklodowska-Curie Actions
Organisme : Junta de Castilla y León
Organisme : European Regional Development Fund
Organisme : Centro de Investigación Biomédica en Red de Cáncer
Organisme : Instituto de Salud Carlos III
Informations de copyright
© 2024 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Références
Horny HP, Sotlar K, Valent P, Hartmann K. Mastocytosis: a disease of the hematopoietic stem cell. Dtsch Arztebl Int. 2008;105(40):686-692. doi:10.3238/arztebl.2008.0686
Valent P, Akin C, Sperr WR, et al. New insights into the pathogenesis of Mastocytosis: emerging concepts in diagnosis and therapy. Annu Rev Pathol. 2023;18:361-386. doi:10.1146/annurev-pathmechdis-031521-042618
Zanotti R, Tanasi I, Crosera L, et al. Systemic Mastocytosis: multidisciplinary approach. Mediterr J Hematol Infect Dis. 2021;13(1):e2021068. doi:10.4084/MJHID.2021.068
Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of Haematolymphoid Tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36(7):1703-1719. doi:10.1038/s41375-022-01613-1
Valent P, Akin C, Hartmann K, et al. Updated diagnostic criteria and classification of mast cell disorders: a consensus proposal. HemaSphere. 2021;5(11):e646. doi:10.1097/HS9.0000000000000646
Valent P, Horny HP, Escribano L, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res. 2001;25(7):603-625. doi:10.1016/s0145-2126(01)00038-8
Gilfillan AM, Rivera J. The tyrosine kinase network regulating mast cell activation. Immunol Rev. 2009;228(1):149-169. doi:10.1111/j.1600-065X.2008.00742.x
Garcia-Montero AC, Jara-Acevedo M, Teodosio C, et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish network on Mastocytosis (REMA) in a series of 113 patients. Blood. 2006;108(7):2366-2372. doi:10.1182/blood-2006-04-015545
Castells M, Metcalfe DD, Escribano L. Diagnosis and treatment of cutaneous mastocytosis in children: practical recommendations. Am J Clin Dermatol. 2011;12(4):259-270. doi:10.2165/11588890-000000000-00000
Tefferi A, Pardanani A. Systemic mastocytosis: current concepts and treatment advances. Curr Hematol Rep. 2004;3(3):197-202.
Escribano L, Akin C, Castells M, Schwartz LB. Current options in the treatment of mast cell mediator-related symptoms in mastocytosis. Inflamm Allergy Drug Targets. 2006;5(1):61-77. doi:10.2174/187152806775269303
Coppé JP, Desprez PY, Krtolica A, Campisi J. The senescence-associated secretory phenotype: the dark side of tumor suppression. Annu Rev Pathol. 2010;5:99-118. doi:10.1146/annurev-pathol-121808-102144
Coppé JP, Patil CK, Rodier F, et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 2008;6(12):2853-2868. doi:10.1371/journal.pbio.0060301
da Silva EZ, Jamur MC, Oliver C. Mast cell function: a new vision of an old cell. J Histochem Cytochem. 2014;62(10):698-738. doi:10.1369/0022155414545334
Elieh Ali Komi D, Grauwet K. Role of mast cells in regulation of T cell responses in experimental and clinical settings. Clin Rev Allergy Immunol. 2018;54(3):432-445. doi:10.1007/s12016-017-8646-z
Cardamone C, Parente R, Feo GD, Triggiani M. Mast cells as effector cells of innate immunity and regulators of adaptive immunity. Immunol Lett. 2016;178:10-14. doi:10.1016/j.imlet.2016.07.003
Bulfone-Paus S, Bahri R. Mast cells as regulators of T cell responses. Front Immunol. 2015;6:394. doi:10.3389/fimmu.2015.00394
Woźniak E, Owczarczyk-Saczonek A, Placek W. Psychological stress, mast cells, and psoriasis-is there any relationship? Int J Mol Sci. 2021;22(24):13252. doi:10.3390/ijms222413252
Valitutti S, Espinosa E. Cognate interactions between mast cells and helper T lymphocytes. Self Nonself. 2010;1(2):114-122. doi:10.4161/self.1.2.11795
Noto CN, Hoft SG, DiPaolo RJ. Mast cells as important regulators in autoimmunity and cancer development. Front Cell Dev Biol. 2021;9:752350. doi:10.3389/fcell.2021.752350
Pérez-Pons A, Jara-Acevedo M, Henriques A, et al. Altered innate immune profile in blood of systemic mastocytosis patients. Clin Transl Allergy. 2022;12(6):e12167. doi:10.1002/clt2.12167
Kulinski JM, Eisch R, Young ML, et al. Skewed lymphocyte subpopulations and associated phenotypes in patients with Mastocytosis. J Allergy Clin Immunol Pract. 2020;8(1):292-301.e2. doi:10.1016/j.jaip.2019.07.004
van der Ploeg EK, Hermans MAW, van der Velden VHJ, Dik WA, van Daele PLA, Stadhouders R. Increased group 2 innate lymphoid cells in peripheral blood of adults with mastocytosis. J Allergy Clin Immunol. 2021;147:1490-1496.e2. doi:10.1016/j.jaci.2020.09.037
Hermans MAW, Heeringa JJ, Swagemakers SGA, et al. Altered leukocyte subsets and immune proteome indicate proinflammatory mechanisms in mastocytosis. J Allergy Clin Immunol. 2022;150(1):146-156.e10. doi:10.1016/j.jaci.2021.12.786
Botafogo V, Pérez-Andres M, Jara-Acevedo M, et al. Age distribution of multiple functionally relevant subsets of CD4+ T cells in human blood using a standardized and validated 14-color EuroFlow immune monitoring tube. Front Immunol. 2020;11:166. doi:10.3389/fimmu.2020.00166
Jara-Acevedo M, Teodosio C, Sanchez-Muñoz L, et al. Detection of the KIT D816V mutation in peripheral blood of systemic mastocytosis: diagnostic implications. Mod Pathol. 2015;28(8):1138-1149. doi:10.1038/modpathol.2015.72
Sotlar K, Escribano L, Landt O, et al. One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes. Am J Pathol. 2003;162(3):737-746. doi:10.1016/S0002-9440(10)63870-9
Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29(9):e45. doi:10.1093/nar/29.9.e45
Lyons JJ, Yu X, Hughes JD, et al. Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number. Nat Genet. 2016;48(12):1564-1569. doi:10.1038/ng.3696
Hernández-Hernández L, Sanz C, Marcos-Vadillo E, et al. Increased TPSAB1 copy number in a family with elevated basal serum levels of tryptase. Front Med. 2021;8:577081. doi:10.3389/fmed.2021.577081
Criado I, Nieto WG, Oliva-Ariza G, et al. Age- and Sex-Matched Normal Leukocyte Subset ranges in the general population defined with the euroflow lymphocyte screening tube (LST) for monoclonal b-cell lymphocytosis (MBL) vs. non-mbl subjects. Cancer. 2022;15(1):58. doi:10.3390/cancers15010058
Saeed AI, Sharov V, White J, et al. TM4: a free, open-source system for microarray data management and analysis. Biotechniques. 2003;34(2):374-378. doi:10.2144/03342mt01
El Hussein S, Chifotides HT, Khoury JD, Verstovsek S, Thakral B. Systemic Mastocytosis and other entities involving mast cells: a practical review and update. Cancer. 2022;14(14):3474. doi:10.3390/cancers14143474
Mekori YA, Hershko AY, Frossi B, Mion F, Pucillo CE. Integrating innate and adaptive immune cells: mast cells as crossroads between regulatory and effector B and T cells. Eur J Pharmacol. 2016;778:84-89. doi:10.1016/j.ejphar.2015.03.087
Gri G, Frossi B, D'Inca F, et al. Mast cell: an emerging partner in immune interaction. Front Immunol. 2012;3:120. doi:10.3389/fimmu.2012.00120
Nakae S, Suto H, Iikura M, et al. Mast cells enhance T cell activation: importance of mast cell costimulatory molecules and secreted TNF. J Immunol. 2006;176(4):2238-2248. doi:10.4049/jimmunol.176.4.2238
Tartaglia LA, Goeddel DV, Reynolds C, et al. Stimulation of human T-cell proliferation by specific activation of the 75-kDa tumor necrosis factor receptor. J Immunol. 1993;151(9):4637-4641.
Bazzoni F, Beutler B. The tumor necrosis factor ligand and receptor families. N Engl J Med. 1996;334(26):1717-1725. doi:10.1056/NEJM199606273342607
Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ. 2003;10(1):45-65. doi:10.1038/sj.cdd.4401189
McLachlan JB, Hart JP, Pizzo SV, et al. Mast cell-derived tumor necrosis factor induces hypertrophy of draining lymph nodes during infection. Nat Immunol. 2003;4(12):1199-1205. doi:10.1038/ni1005
Nakajima T, Inagaki N, Tanaka H, et al. Marked increase in CC chemokine gene expression in both human and mouse mast cell transcriptomes following Fcepsilon receptor I cross-linking: an interspecies comparison. Blood. 2002;100(12):3861-3868. doi:10.1182/blood-2002-02-0602
Sayama K, Diehn M, Matsuda K, et al. Transcriptional response of human mast cells stimulated via the fc(epsilon)RI and identification of mast cells as a source of IL-11. BMC Immunol. 2002;3:5. doi:10.1186/1471-2172-3-5
Lavender N, Yang J, Chen SC, et al. The yin/Yan of CCL2: a minor role in neutrophil anti-tumor activity in vitro but a major role on the outgrowth of metastatic breast cancer lesions in the lung in vivo. BMC Cancer. 2017;17(1):88. doi:10.1186/s12885-017-3074-2
Li H, Wu M, Zhao X. Role of chemokine systems in cancer and inflammatory diseases. MedComm. 2022;3(2):e147. doi:10.1002/mco2.147
Ji T, Li H. T-helper cells and their cytokines in pathogenesis and treatment of asthma. Front Immunol. 2023;14:1149203. doi:10.3389/fimmu.2023.1149203
Gutiérrez-Melo N, Baumjohann D. T follicular helper cells in cancer. Trends Cancer. 2023;9(4):309-325. doi:10.1016/j.trecan.2022.12.007
Yoshitomi H, Ueno H. Shared and distinct roles of T peripheral helper and T follicular helper cells in human diseases. Cell Mol Immunol. 2021;18(3):523-527. doi:10.1038/s41423-020-00529-z
Escribano L, Alvarez-Twose I, Sánchez-Muñoz L, et al. Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish network on Mastocytosis in a series of 145 patients. J Allergy Clin Immunol. 2009;124(3):514-521. doi:10.1016/j.jaci.2009.05.003
Muñoz-González JI, Álvarez-Twose I, Jara-Acevedo M, et al. Frequency and prognostic impact of KIT and other genetic variants in indolent systemic mastocytosis. Blood. 2019;134(5):456-468. doi:10.1182/blood.2018886507
Gotlib J, Kluin-Nelemans HC, George TI, et al. Efficacy and safety of Midostaurin in advanced systemic Mastocytosis. N Engl J Med. 2016;374(26):2530-2541. doi:10.1056/NEJMoa1513098
Hartmann K, Gotlib J, Akin C, et al. Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis. J Allergy Clin Immunol. 2020;146(2):356-366.e4. doi:10.1016/j.jaci.2020.03.044
Alvarez-Twose I, Zanotti R, González-de-Olano D, et al. Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM. J Allergy Clin Immunol. 2014;133(2):520-528. doi:10.1016/j.jaci.2013.06.020
Gurram RK, Zhu J. Orchestration between ILC2s and Th2 cells in shaping type 2 immune responses. Cell Mol Immunol. 2019;16(3):225-235. doi:10.1038/s41423-019-0210-8
Kubo M. T follicular helper and TH2 cells in allergic responses. Allergol Int. 2017;66(3):377-381. doi:10.1016/j.alit.2017.04.006
Boehm T, Ristl R, Mühlbacher J, Valent P, Wahrmann M, Jilma B. Massive release of TH2 cytokines induced a cytokine storm during a severe mast cell activation event in a patient with indolent systemic mastocytosis. J Allergy Clin Immunol. 2022;150(2):406-414.e16. doi:10.1016/j.jaci.2022.04.023
Jafarzadeh A, Larussa T, Nemati M, Jalapour S. T cell subsets play an important role in the determination of the clinical outcome of helicobacter pylori infection. Microb Pathog. 2018;116:227-236. doi:10.1016/j.micpath.2018.01.040
Pan Y, Du D, Wang L, Wang X, He G, Jiang X. The role of T helper 22 cells in dermatological disorders. Front Immunol. 2022;13:911546. doi:10.3389/fimmu.2022.911546
Zhang N, Pan HF, Ye DQ. Th22 in inflammatory and autoimmune disease: prospects for therapeutic intervention. Mol Cell Biochem. 2011;353(1-2):41-46. doi:10.1007/s11010-011-0772-y
Tamasauskiene L, Sitkauskiene B. Role of Th22 and IL-22 in pathogenesis of allergic airway diseases: pro-inflammatory or anti-inflammatory effect? Pediatr Neonatol. 2018;59(4):339-344. doi:10.1016/j.pedneo.2017.11.020
Kranyak A, Shuler M, Lee LW. Cutaneous manifestations in hereditary alpha Tryptasemia. Cutis. 2023;111(1):49-52. doi:10.12788/cutis.0682
Wang M, Tian T, Yu S, He N, Ma D. Th17 and Treg cells in bone related diseases. Clin Dev Immunol. 2013;2013:203705. doi:10.1155/2013/203705
Bettelli E, Oukka M, Kuchroo VK. T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol. 2007;8(4):345-350. doi:10.1038/ni0407-345
Cheru N, Hafler DA, Sumida TS. Regulatory T cells in peripheral tissue tolerance and diseases. Front Immunol. 2023;14:1154575. doi:10.3389/fimmu.2023.1154575
Rama TA, Henriques AF, Matito A, et al. Bone and cytokine markers associated with bone disease in systemic Mastocytosis. J Allergy Clin Immunol Pract. 2023;11(5):1536-1547. doi:10.1016/j.jaip.2023.02.007